Medical isotope developer IsoRay is highlighting data that show that brachytherapy with the isotope cesium-131 is beneficial for prostate cancer patients -- and offers a less invasive and less costly treatment alternative to surgery or radiation treatment.
The study, published in the August issue of the International Journal of Radiation Oncology, Biology and Physics, found that patients treated with cesium-131 prostate brachytherapy showed minimal long-term changes in urinary or bowel patient-reported quality of life scores at median follow-up of 5.5 years post-treatment (Int J Radiat Oncol Biol Phys, August 2017, Vol. 98:5, pp. 1053-1058).
"These findings suggest that patients treated with this isotope are able to recover and then maintain their baseline quality of life in the long term," wrote a team led by Dr. Scott Glaser of the University of Pittsburgh Cancer Institute.
